OnKure Therapeutics, Inc. (OKUR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

OnKure Therapeutics, Inc. (OKUR) Healthcare & Pipeline Overview

OnKure Therapeutics, Inc. is a biotechnology firm specializing in oncology-precision medicines, with a focus on developing selective inhibitors of histone deacetylases. Their lead candidate, OKI-179, aims to treat hematological and solid tumors, positioning them in the competitive oncology therapeutics market.

What Is the Investment Thesis for OKUR?

OnKure Therapeutics presents a focused investment opportunity within the oncology-precision medicine space. The company's lead candidate, OKI-179, targeting both hematological and solid tumors, addresses a significant market need. Key value drivers include the successful completion of ongoing clinical trials and potential FDA approval of OKI-179. The company's small size (46 employees) allows for agility but also introduces execution risk. A beta of 0.15 suggests low volatility relative to the market. Growth catalysts include positive clinical trial data releases and potential partnerships with larger pharmaceutical companies. However, the lack of dividend yield may deter some investors. The company's market capitalization of $159M reflects its early-stage nature and associated risks.

Based on FMP financials and quantitative analysis

OKUR Key Highlights

OnKure Therapeutics focuses on oncology-precision medicines, indicating a targeted approach to cancer treatment.

• OKI-179, their lead product, is designed to treat both hematological and solid tumors, potentially addressing a broad patient population.
• The company was founded in 2011, suggesting a relatively young but established presence in the biotechnology sector.
• Based in Boulder, Colorado, OnKure benefits from a location known for its biotechnology innovation and talent pool.
• The company has 46 employees, reflecting a lean and focused operational structure.

Who Are OKUR's Competitors?

OKUR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OKUR's Key Strengths?

Focused on oncology-precision medicines.

• Proprietary HDAC inhibitor technology.
• Lead product candidate targeting both hematological and solid tumors.
• Experienced management team.

What Are OKUR's Weaknesses?

Limited financial resources.

• Small size and limited infrastructure.
• Reliance on a single drug candidate.
• High risk of clinical trial failure.

What Could Drive OKUR Stock Higher?

Release of clinical trial data for OKI-179 in hematological malignancies.

• Initiation of Phase 2 clinical trial for OKI-179 in solid tumors.
• Enrollment of patients in ongoing clinical trials.
• Partnering discussions with larger pharmaceutical companies.

What Are the Key Risks for OKUR?

Negative return on equity (-61.0%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of OKI-179 in clinical trials.
• Delays in regulatory approval processes.
• Competition from other oncology therapies.
• Dependence on external funding to support research and development.
• Patent challenges to its proprietary technology.

What Are the Growth Opportunities for OKUR?

• Advancement of OKI-179 through Clinical Trials: OnKure's primary growth opportunity lies in the successful advancement of OKI-179 through ongoing clinical trials. Positive clinical data demonstrating efficacy and safety could significantly increase the company's valuation and attract potential partnerships. The timeline for clinical trial completion and potential FDA approval is estimated to be within the next 3-5 years, representing a significant near-term catalyst.
• Expansion of HDAC Inhibitor Pipeline: OnKure has the opportunity to expand its pipeline of HDAC inhibitors beyond OKI-179. By identifying and developing new compounds targeting different HDAC isoforms or cancer types, the company can diversify its product portfolio and reduce reliance on a single drug candidate. This expansion could involve preclinical research, licensing agreements, or strategic acquisitions. The timeline for developing new HDAC inhibitors is estimated to be 5-7 years, representing a longer-term growth opportunity. The market for HDAC inhibitors is expected to grow as new applications and combination therapies are discovered.
• Strategic Partnerships with Pharmaceutical Companies: OnKure can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its oncology-precision medicines. These partnerships could involve licensing agreements, co-development agreements, or joint ventures. Partnering with a larger company would provide OnKure with access to additional funding, expertise, and resources, as well as a broader distribution network. The timeline for securing strategic partnerships is estimated to be within the next 1-2 years, representing a near-term growth opportunity. The potential financial benefits of these partnerships could be substantial, including upfront payments, milestone payments, and royalties on future sales.
• Exploration of Combination Therapies: OnKure can explore the potential of combining its HDAC inhibitors with other cancer therapies, such as chemotherapy, immunotherapy, or targeted therapies. Combination therapies may offer synergistic effects and improve treatment outcomes for patients with cancer. This strategy could involve preclinical research, clinical trials, and collaborations with other companies. The timeline for developing combination therapies is estimated to be 3-5 years, representing a medium-term growth opportunity. The market for combination therapies is expected to grow as personalized medicine becomes more prevalent.
• Expansion into New Cancer Indications: OnKure can expand its focus beyond hematological and solid tumors to include other cancer indications, such as rare cancers or pediatric cancers. This expansion would require additional research and development efforts, but it could significantly increase the company's addressable market. The timeline for expanding into new cancer indications is estimated to be 5-7 years, representing a longer-term growth opportunity. The potential financial benefits of this expansion could be substantial, as many rare and pediatric cancers have limited treatment options and unmet medical needs.

What Threats Does OKUR Face?

• Competition from larger pharmaceutical companies.
• Regulatory hurdles and lengthy approval processes.
• Patent challenges.
• Changes in healthcare policy.

What Are OKUR's Competitive Advantages?

• Proprietary HDAC inhibitor technology.
• Patent protection for its drug candidates.
• Expertise in oncology-precision medicine.
• First-mover advantage in targeting specific HDAC isoforms.

What Does OKUR Do?

Founded in 2011 and based in Boulder, Colorado, OnKure Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of innovative oncology-precision medicines. The company's core focus lies in creating selective inhibitors of histone deacetylases (HDACs), a class of enzymes that play a crucial role in gene expression and cellular processes. By targeting HDACs, OnKure aims to develop therapies that can selectively disrupt cancer cell growth and survival. Their lead product candidate, OKI-179, is being developed for the treatment of both hematological malignancies (blood cancers) and solid tumors. OnKure's research and development efforts are centered around advancing OKI-179 through clinical trials and exploring additional HDAC inhibitors for various cancer indications. The company operates with a team of 46 employees, reflecting a focused and agile approach to drug development within the competitive biotechnology landscape. OnKure's strategy involves identifying and developing targeted therapies that address unmet needs in cancer treatment, with the goal of improving patient outcomes and quality of life. The company is committed to rigorous scientific research and clinical evaluation to bring its innovative therapies to market.

What Products and Services Does OKUR Offer?

• Discovers and develops oncology-precision medicines.
• Focuses on selective inhibitors of histone deacetylases (HDACs).
• Develops therapies for the treatment of cancer.
• Targets both hematological and solid tumors.
• Conducts preclinical and clinical research to advance drug candidates.
• Seeks regulatory approval for its drug candidates.

How Does OKUR Make Money?

• Develops and patents novel oncology therapeutics.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through licensing fees, milestone payments, and royalties.
• Raises capital through equity financing to fund research and development.

What Industry Does OKUR Operate In?

OnKure Therapeutics operates within the biotechnology industry, specifically focusing on oncology-precision medicines. The global oncology market is substantial and growing, driven by an aging population and advancements in cancer diagnostics and treatment. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms developing targeted therapies. OnKure's focus on HDAC inhibitors positions it within a niche segment of the oncology market, targeting specific molecular mechanisms involved in cancer development. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition for market share.

Who Are OKUR's Key Customers?

• Patients with hematological malignancies (blood cancers).
• Patients with solid tumors.
• Hospitals and oncology clinics.
• Pharmaceutical companies seeking to expand their oncology portfolios.

How OnKure Therapeutics, Inc. Is Valued

OnKure Therapeutics, Inc. carries a market capitalization of $159M, placing it in the micro-cap category. Relative to its peer group, OKUR's quantitative score of 57/100 is roughly in line with the peer average of 67/100.

Company Profile

OnKure Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boulder, US. The company is led by CEO Nicholas A. Saccomano. OKUR has traded publicly since 2021.

Return on equity for OnKure Therapeutics, Inc. stands at -61.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -82.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 13.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -95.5%, the inverse of the P/E and a quick read on earnings relative to price.

OnKure Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.84 places it in the safe zone, indicating low near-term bankruptcy risk.

Wall Street analysts project OnKure Therapeutics, Inc. revenue of about $333K for fiscal 2026, with EPS near $-1.83. The estimate reflects 3 contributing analysts.

OKUR Financials

OKUR Latest News

OKUR Analyst Consensus

OKUR MoonshotScore

OnKure Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources